본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

American journal of hematology v.93 no.7, 2018년, pp.859 - 866  

Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT

Gorin, Norbert Claude (Department of Hematology and Cell Therapy and EBMT Office, Hôpital Saint‐Antoine APHP, INSERM U 938, Université ) ; Labopin, Myriam (Pierre et Marie Curie UPMC, Paris, France ) ; Blaise, Didier (Department of Hematology and Cell Therapy and EBMT Office, Hôpital Saint‐Antoine APHP, INSERM U 938, Université ) ; Dumas, Pierre‐Yves (Pierre et Marie Curie UPMC, Paris, France ) ; Pabst, Thomas (Institut Paoli Calmettes, Marseille, France ) ; Trisolini, Silvia Maria (CHU Bordeaux, Service d'hématologie clinique et thérapie cellulaire, Bordeaux, F 33000, France ) ; Arcese, William (Department of Medical Oncology, Inselspital, University Hospital Bern, Bern, CH‐3010, Switzerland ) ; Houhou, Mohamed (Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy ) ; Mohty, Mohamad (Rome Transplant Network, ¨Tor Vergata¨ ) ; Nagler, Arnon ;
  • 초록  

    Abstract Autologous stem cell transplantation remains a clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a small cohort of patients, we have previously shown better outcomes following Busulfan and Melphalan (BUMEL) over Busulfan and Cyclophosphamide (BUCY). To identify the subpopulations that might get the highest benefit with BUMEL, we designed a larger study. All adult patients with primary AML and available cytogenetics, autografted from January 2000 to December 2016 in CR1, were included: 1137 patients received BUCY and 512 BUMEL. All factors differing in distribution between the 2 conditioning groups were introduced in multivariate analyzes. In a primary analysis, we found an interaction between conditioning and the poor risk group defined as poor cytogenetics and/or presence of the FLT3‐ITD mutation. During analysis of the poor risk group, 176 patients received BUCY and 62 BUMEL. BUMEL was associated with a lower RI at 5 years (53% versus 69%, HR: 0.52, P = .002), a better Leukaemia‐free survival (LFS) (42% versus 25%, HR: 0.54, P = .002) and a better OS (54% versus 36%, HR: 0.61, P = .02). During analysis of the non poor risk group, 961 patients received BUCY and 450 BUMEL. At 5 years, the RI was 50% and 47%, the LFS 45% and 48% and the OS 56% and 60% respectively, with no significant difference. We conclude that BUMEL is the preferable conditioning regimen for the poor risk leukemic patients, while in AML patients without poor risk cytogenetics or FLT3 both conditioning regimens are valid.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기